Physician profile
Donna E Burrell
NPI 1891782066
$10,541.67
in general payments reported to CMS, 2019-2025
39 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,282 · 2020: $905 · 2021: $1,507 · 2022: $1,414 · 2023: $1,762 · 2024: $1,931 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,433.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,505.00 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,497.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,347.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,149.53 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $779.88 | 2021-2025 | |
| Glaxosmithkline, LLC. | $750.34 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $488.52 | 2019-2025 | |
| Astellas Pharma US INC | $476.26 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $437.62 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $333.52 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $311.97 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $234.25 | 2019-2023 | |
| Abbvie INC. | $201.88 | 2021-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $190.22 | 2019-2025 | Verquvo, Belsomra, Steglujan |
| Otsuka America Pharmaceutical, INC. | $117.35 | 2022-2025 | Rexulti |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Burrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.